Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $7.24 USD
Change Today +0.04 / 0.56%
Volume 73.8K
VCYT On Other Exchanges
As of 8:10 PM 11/25/15 All times are local (Market data is delayed by at least 15 minutes).

veracyte inc (VCYT) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/24/15 - $12.47
52 Week Low
09/30/15 - $4.59
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for VERACYTE INC (VCYT)

Related News

No related news articles were found.

veracyte inc (VCYT) Related Businessweek News

No Related Businessweek News Found

veracyte inc (VCYT) Details

Veracyte, Inc. operates as a molecular diagnostics company in the United States. It operates in the field of molecular cytology with genomic solutions that resolve diagnostic ambiguity and enable physicians to make informed treatment decisions at an early stage in patient care. The company offers Afirma Thyroid FNA Analysis solution for use in thyroid cancer diagnosis; cytopathology testing services; and the Afirma Malignancy Classifiers, which comprise the genomic tests for medullary thyroid cancer and BRAF V600E mutation status. It also develops a product to preoperatively identify idiopathic pulmonary fibrosis among patients presenting with a suspected interstitial lung disease; and the Percepta Bronchial Genomic Classifier, a lung cancer test that would identify patients with non-diagnostic bronchoscopy results whose nodules are at low risk of being cancerous. Veracyte, Inc. serves endocrinologists; radiologists; and ear, nose, and throat physicians. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

167 Employees
Last Reported Date: 03/25/15
Founded in 2006

veracyte inc (VCYT) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $425.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $300.0K
Chief Operating Officer
Total Annual Compensation: $341.2K
Compensation as of Fiscal Year 2014.

veracyte inc (VCYT) Key Developments

Veracyte, Inc. Appoints Tina S. Nova as Director and Chairman of the Regulatory and Compliance Committee

Effective November 12, 2015, the Board of Directors of Veracyte, Inc. elected Tina S. Nova, Ph.D. to the company's Board of Directors. In addition to serving on the Board of Directors, Dr. Nova will also serve as Chairman of the Regulatory and Compliance Committee of the Board of Directors. Dr. Nova, age 62, is a life sciences industry veteran with extensive experience building and leading novel genomics-based businesses. Since October 2015, she has served as president and chief executive officer of Molecular Stethoscope, Inc., a molecular diagnostics company.

Veracyte, Inc. Reports Unaudited Earnings Results for the Third Quarter and Nine Months Ended September 30, 2015; Reiterates Revenue Guidance for the Year 2015

Veracyte, Inc. reported unaudited earnings results for the third quarter and nine months ended September 30, 2015. For the quarter, revenue was $12.3 million, an increase of 25%, compared to $9.8 million for the third quarter of 2014. Net loss for the third quarter of 2015 was $8.9 million, or $0.32 per common share, versus a net loss of $7.9 million, or $0.37 per common share, for the same period in 2014. Loss from operations was $8,888,000 compared to $7,811,000 a year ago. For the nine months, revenue was $35,461,000, compared to $25,991,000 for the same period in 2014. Loss from operations was $25,515,000 compared to $20,947,000 a year ago. Net loss was $25,691,000, or $1.01 per basic and diluted share compared to a net loss of $21,231,000 or $0.99 per basic and diluted share for the same period in 2014. The company reiterated its 2015 annual revenue guidance of $48 million to $53 million.

Veracyte, Inc. to Report Q3, 2015 Results on Nov 05, 2015

Veracyte, Inc. announced that they will report Q3, 2015 results at 5:15 PM, US Eastern Standard Time on Nov 05, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VCYT:US $7.24 USD +0.04

VCYT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Exact Sciences Corp $8.89 USD -0.20
Foundation Medicine Inc $16.33 USD -0.06
PDI Inc $0.75 USD -0.02
Rosetta Genomics Ltd $1.42 USD -0.10
Trovagene Inc $6.98 USD +0.44
View Industry Companies

Industry Analysis


Industry Average

Valuation VCYT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.2x
Price/Book 3.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 3.1x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact VERACYTE INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at